



Amendments to the Claims

1. Cancelled.
2. Cancelled.
3. Cancelled.
4. Cancelled.
5. Cancelled.
6. Cancelled.
7. Cancelled.
8. Cancelled.
9. Cancelled.
10. Cancelled.
11. Cancelled.
11. Cancelled.
12. Cancelled.
13. Cancelled.
14. Cancelled.
15. Cancelled.
16. (Original) A process for preparing a compound of Formula XI




FORMULA XI

($R_{16} = -CH_2F$ or $-CH_2F_2$) by reacting a compound of Formula IX



FORMULA IX


with sodium borohydride to produce a compound of Formula X



FORMULA X


and further reacting this compound with diethylamino sulfurtrifluoride to produce compound of Formula XI.

17. (Original) A process for preparing a compound of Formula XII



FORMULA XII


wherein $R_{17} = \text{---} = N-OH$ which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX

with hydroxylamine.


18. (Original) A process for preparing a compound of Formula XII



FORMULA XII

wherein $R_{17} = \text{CH}_2\text{N}=\text{N}-\text{NH}_2$ which comprises reacting (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide with hydrazine hydrate.


19. (Original) A process for preparing a compound of Formula XII



FORMULA XII

wherein $R_{17} = \text{CH}_2\text{N}=\text{O}-\text{C}(=\text{O})-\text{NH}-\text{C}_6\text{H}_4-\text{CH}_2\text{COOCH}_3$ which comprises reacting (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl]] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with isocyanate.


20. (Original) A process for preparing a compound of Formula XII



FORMULA XII

wherein $R_{17} = \text{CN}$ which comprises reacting (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}]]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with triflic anhydride and triethylamine.


21. (Original) A process for preparing a compound of Formula XII



FORMULA XII


wherein $R_{17} = -\text{CH}(\text{OCH}_2\text{CH}_2\text{O})$ which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with 1,3-propane diol and BF_3 etherate.

22. (Original) A process for the preparation of the compound of Formula XIV




FORMULA XIV

wherein $R_{18} = -\text{C}(=\text{O})\text{NH}_2$ which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX


with Ag_2O to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl]phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII




FORMULA XIII

with aqueous ammonia to produce Formula XIV.


23. (Original) A process for the preparation of the compound of Formula XIV



FORMULA XIV




which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX


with Ag_2O to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII




FORMULA XIII

with thionyl chloride to produce Formula XIV.


24. (Original) A process for the preparation of the compound of Formula XIV



FORMULA XIV




which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX


with Ag_2O to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII



FORMULA XIII

with morpholine in the presence of oxalyl chloride to produce Formula XIV.

25. (Currently Amended) A compound having the structure of Formula I



FORMULA I

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein T is five- to seven-membered heterocyclic ring, aryl, substituted aryl, bound to the ring C with a linker W and the heterocyclic and aryl rings are further substituted by a group represented by R, wherein R is selected from the group consisting of hydrogen, alkyl (C₁₋₆), halogen, -CN, COR₅, COOR₅, N(R₆, R₇), CON (R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH = N-OR₁₀, -C=CH-R₅, wherein R₅ is selected from the group consisting of H, optionally substituted C₁-C₁₂, alkyl, C₃₋₁₂, cycloalkyl, aryl, heteroaryl; R₆ and R₇ are independently selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy; R₈ and R₉ are independently selected from the group consisting of H, C₁₋₆ alkyl, F, Cl, Br, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, OR₄, SR₄, N(R₆, R₇) wherein R₄ is selected from the group consisting of H, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl substituted with one or more F, Cl, Br, I or OH and R₆ and R₇ are the same as defined earlier, R₁₀ is selected from the

group consisting of H, optionally substituted from H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆, alkoxy, C₁₋₆ alkyl, aryl, heteroaryl;

n is 1;

X is N

Y and Z are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, and C₃₋₁₂ cycloalkyl;


U and V are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, F, Cl, Br, and C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I;

W is selected from the group CH₂, CO, CH₂NH, NHCH₂, CH₂NHCH₂, CH₂N(R₁₁)CH₂, -CO-CO-, CH₂(R₁₁)N-, CH(R₁₁)S-, CH₂(CO), N(R₁₁) wherein R₁₁ is hydrogen, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl or heteroaryl;

R₁ is selected from the group consisting of -NHC(=O)R₂ wherein R₂ is hydrogen, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl substituted with one or more of F, Cl, Br, I or OH; N(R₃, R₄); -NR₂C(=S)R₃; -NR₂C(=S)SR₃ wherein R₂ is the same as defined above and R₃ and R₄ are independently selected from the group consisting of H, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl substituted with one or more of F, Cl, Br, I or OH;

with the proviso that when R₁ is NHAc, and one of U or V is halogen, and W is (CO), and T is isoxazole, then R cannot be cyano, (C(O)NH₂, C(O)N(CH₃)₂, CO₂H, or CH₃, and when R₁ is NHAc, and one of U or V is halogen, and W is CH₂, and T is isoxazole, then R cannot be CH₃.

26. (Currently Amended) A compound having structure of Formula II



FORMULA II

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein

M= O, S, NH, N-CH₃;

X is N;

Y and Z are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, and C₃₋₁₂ cycloalkyl;


U and V are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, F, Cl, Br, and C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I;

W is selected from the group consisting of CH₂, CO, ~~CH₂NH, NHCH₂, CH₂NHCH₂, CH₂N~~
~~(R₁₁)-CH₂, CH₂(R₁₁)-N, CH(R₁₁), S, CH₂(CO), NH~~ wherein ~~R₁₁ is optionally substituted~~
~~with C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl except when~~
~~M=S, Q=P=H, W=(C=O) with the proviso that when M is sulphur, and when W is (CO), then Q~~
~~and P cannot be hydrogen;~~


n is 1; and,

Q and P are independently selected from the group consisting of hydrogen, -CN, COR₅, COOR₅,
 N(R₆, R₇), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH=N-OR₁₀, C=CH-R₅, wherein R₅ is
 selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, aryl,
 heteroaryl; R₆ and R₇ are independently selected from the group consisting of H, optionally

substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4 , SR_4 , wherein R_4 is selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more F, Cl, Br, I or OH, $N(R_6, R_7)$, R_{10} is selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl ~~except $W = (CO)$, Q and $P = H$ and $M = S$, wherein $M =$ Sulphur and Oxygen~~ as shown by Formulae III and IV respectively,



FORMULA III



Formula IV

wherein P, Q, U, V, X, Y, Z, W and n in Formulae III and IV as defined earlier for Formula I.

27. (Currently Amended) A compound selected from the group consisting of

1. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furoyl) piperazinyl]]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
2. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

3. (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
4. (S)-N-[[3-Fluoro-4-[N-1[4-(5-bromo-2-furoyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide
5. (S)-N-[[3-Fluoro-4-[N-1[4-(5-chloromethyl-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
6. (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide
7. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-(2-thienyl)dicarbonyl}]]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
8. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl] acetamide
9. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-bromo)methyl}]]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
10. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-chloro)methyl}]]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
11. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide
12. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-thienylmethyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
13. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide
14. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(4-bromo)methyl}]]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
15. (S)-N-[[3-[3-fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}]]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
16. Hydrochloric salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
17. Citrate salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
18. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-pyrrolylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide


19. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(3-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
20. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
21. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
22. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-pyrrole(1-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
23. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
24. (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-thiomorpholinyl)methyl}methyl]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
25. (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-morpholinyl)methyl}methyl]]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
26. (S)-N[[3-Fluoro-4-[N-1[4-{2-furyl(5-acetoxymethyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide
27. (S)-N[[3-Fluoro-4-[N-1[4-{2-thienyl(5-bromo)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide
28. (S)-N[[3-Fluoro-4-[N-1[4-(5-nitro-2-furylmethyl)piperazinyl]phenyl]-2-oxo-oxazolidinyl)methyl]dichloroacetamide
29. (S)-N[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-thienoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide hydrochloride
30. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2',2'-diphenyl-2'-hydroxy acetyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
59. (S)-N[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl)methyl]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide.
60. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-furyl(5-aldoxime)methyl]]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide
61. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenyl acetate)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide

62. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide
 63. (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl) methyl}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide
 64. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 65. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenyl acetate) methyl})]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 66. (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide
 67. (S)-N-[[3-[3-Fluoro-4-[N-1{2-furyl-[4-(5-hydroxymethyl)methyl}] piperazinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 68. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}] piperazinyl]phenyl] -2-oxo-5-oxazolidinyl]methyl]acetamide
 69. (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
 70. (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
 71. (S)-N-[[3-Fluoro-4-[N-1[5-(formamido)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
 72. (S)-N-[[3-Fluoro-4-[N-1[5-(morpholine-1-carbonyl)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
 73. (S)-N-[[3-Fluoro-4-[N-1[5-(4-(tert butoxy carbonyl)amino piperidine)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
 74. (S)-N-[[3-Fluoro-4-[N-1[4-{{(Z)-2-methoxyimino-2-(2-furyl)acetyl}}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
28. (Previously Added) A pharmaceutical composition comprising the compound of claims 25, 26, or 27 and a pharmaceutically acceptable carrier.
29. (Previously Added) A pharmaceutical composition comprising a pharmaceutically effective amount of compound according to claims 25, 26 or 27, or a physiologically acceptable

acid addition salt thereof with a pharmaceutically acceptable carrier for treating microbial infections.

30. (Previously Added) A method of treating or preventing microbial infections in a mammal comprising administering to the said mammal, the pharmaceutical composition according to claim 29.

31. (Currently Amended) A process for preparing a compound of Formula I



FORMULA I

and its pharmaceutically acceptable salts, enantiomers, diastereomers, or N-oxides, wherein **T** is five to seven membered heterocyclic ring, aryl, substituted aryl, bound to the ring **C** with a linker **w** and the heterocyclic and aryl rings are further substituted by a group represented by **R**, wherein **R** is selected from the group consisting of hydrogen, $-\text{CN}$, COR_5 , COOR_5 , $\text{N}(\text{R}_6, \text{R}_7)$, $\text{CON}(\text{R}_6, \text{R}_7)$, CH_2NO_2 , NO_2 , CH_2R_8 , CHR_9 , $-\text{CH}=\text{N}-\text{OR}_{10}$, $-\text{C}=\text{CH}-\text{R}_5$, wherein R_5 is selected from the group consisting of H, optionally substituted C_{1-12} , alkyl, C_{3-12} , cycloalkyl, aryl, heteroaryl, R_6 and R_7 , are independently selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4 , SR_4 , $\text{N}(\text{R}_6, \text{R}_7)$ wherein R_4 is selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more F, Cl, Br, I or OH and R_6 and R_7 are the same as defined earlier, R_{10} is selected from the group consisting of H, optionally substituted from H, optionally substituted C_{1-12} alkyl, C_{3-512} cycloalkyl, C_{1-6} , alkoxy, C_{1-6} alkyl, aryl, heteroaryl;

n is 1;

X is N;


Y and Z are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, and C₃₋₁₂ cycloalkyl;

U and V are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, F, Cl, Br, and C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I;

W is selected from the group consisting of CH₂, CO, ~~CH₂NH, NHCH₂, CH₂NHCH₂, CH₂N~~
~~(R₁₁)CH₂, CH₂(R₁₁)N, CH(R₁₁), S, CH₂(CO), NH~~ wherein R₁₁ is optionally substituted
 with C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl; and

R₁ is selected from the group consisting of -NHC(=O)R₂ wherein R₂ is hydrogen, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl substituted with one or more of F, Cl, Br, I or OH; N(R₃, R₄)
 ; -NR₂C(=S)R₃ : -NR₂C(=S)SR₃ wherein R₂ is the same as defined above and R₃ and R₄ are
 independently selected from the group consisting of H, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy,
 C₁₋₆ alkyl substituted with one or more of F, Cl, Br, I or OH,

which comprises reacting an amine compound of Formula V



FORMULA V


with a heterocyclic compound of Formula R-T-W- R₁₂ wherein G in amines of Formula V is defined as NH and Y, Z, U, V, R₁, n, R, T and W are the same as defined earlier and R₁₂ is a leaving group selected from the group consisting of -CHO, fluoro, chloro, bromo, SCH₃, -SO₂CH₃, -SO₂CF₃ or OC₆H₅;

with the proviso that when R_1 is NHAc, and one of U or V is halogen, and W is (CO), and T is isoxazole, then R cannot be cyano, $C(O)NH_2$, $C(O)N(CH_3)_2$, CO_2H , or CH_3 , and when R_1 is NHAc, and one of U or V is halogen, and W is CH_2 , and T is isoxazole, then R cannot be CH_3 .

32. (Currently Amended) A process for preparing a compound of Formula I as claimed in claim 31, wherein $W=CH_2$ and R-T-W- R_{12} is a five membered heterocyclic ring with aldehyde group and the compound of Formula I is produced by reductive amination with the proviso that when R_1 is HHAc, and one of U or V is halogen, and W is CH_2 , and T is isoxazole, then R cannot be CH_3 .

33. (Previously Added) A process for preparing a compound of Formula I as claimed in claim 31, wherein $W = CO$ and R-T-W- R_{12} is a five membered heterocyclic ring with carboxylic acid, and amino compound of Formula V is acylated with activated esters in presence of condensing agents comprising 1,3-dicyclohexylcarbodiimide (DCC) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC).

34. (Currently Amended) A process for the preparation of compound of Formula II



FORMULA II

wherein

n is 1;

X is N;


Y and Z are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, and C_{3-12} cycloalkyl;

U and V are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6} alkyl, F, Cl, Br, and C_{1-12} alkyl substituted with one or more of F, Cl, Br, I;

W is selected from the group consisting of CH_2 , CO , ~~CH_2NH , NHCH_2 , CH_2NHCH_2 , CH_2N~~
 ~~$(\text{R}_{11})\text{CH}_2$, $\text{CH}_2(\text{R}_{11})\text{N}$, $\text{CH}(\text{R}_{11})$, S , $\text{CH}_2(\text{CO})$, NH~~ wherein R_{11} is optionally substituted
 with C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl; and


Q and P are independently selected from the group consisting of hydrogen, $-\text{CN}$, COR_5 , COOR_5 ,
 $\text{N}(\text{R}_6, \text{R}_7)$, $\text{CON}(\text{R}_6, \text{R}_7)$, CH_2NO_2 , NO_2 , CH_2R_8 , CHR_9 , $-\text{CH}=\text{N}-\text{OR}_{10}$, $\text{C}=\text{CH}-\text{R}_5$, wherein R_5 is
 selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, aryl,
 heteroaryl; R_6 and R_7 are independently selected from the group consisting of H, optionally
 substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from
 the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl,
 Br, I, OR_4 , SR_4 , wherein R_4 is the same as defined before, $\text{N}(\text{R}_6, \text{R}_7)$, R_{10} is selected from the
 group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl,
 aryl, heteroaryl except $\text{W}=(\text{CO})$, Q and $\text{P}=\text{H}$. with the proviso that when M is sulphur and W is
 (CO) , then Q and P cannot be hydrogen;

wherein M = Sulphur is shown by compounds of Formula III,




FORMULA III

wherein P, Q, U, V, X, Y, Z, W and n in Formula III are the same as previously defined, wherein
 the process comprising reacting a compound of Formula V



FORMULA V

with a compound of Formula VI



FORMULA VI

wherein the transformation is carried out in the presence of carbon monoxide and a catalyst,

wherein P, Q, R₁₂, Y, Z, G, n, U and V are the same as defined earlier, R₁₂ is a leaving group selected from the group consisting of -CHO, fluoro, chloro, bromo, SCH₃, -SO₂CH₃, -SO₂CF₃ or OC₆H₅, G is NH.

35. (Previously Added) A process for preparing a compound of Formula II as claimed in claim 34, in a solvent selected from the group consisting of dimethylformamide, dimethylacetamide, ethanol or ethylene glycol at a temperature in the range of -70°C to 180°C in the presence of a base selected from the group consisting of triethyl amine, diisopropyl amine, potassium carbonate and sodium bicarbonate.

36. (Previously Added) A process of preparing a compound of Formula II as claimed in claim 34, wherein Formula VI is furaldehyde and reductive alkylation of the amine of Formula V is performed with a reducing agent.

37. (Previously Added) A process for preparing a compound of Formula II as claimed in claim 34, wherein Formula VI is furoic acid.

38. (Currently Amended) A process for preparing a compound of Formula II as claimed in claim 34, wherein the compounds of Formula II having carbonyl link are prepared by reacting a heteroaromatic compound of the Formula VI including ~~N-methyl pyrrole~~ with the intermediate amine of Formula V in the presence of triphosgene or phosgene and carbonyl linkers are introduced between heteroaromatic compound comprising reacting 3- bromothiophene and amine of Formula V with carbon monoxide and the catalyst is selected from the group consisting of Pd (PPh₃)₂Cl₂ and extended chain pyrroles having dicarbonyl linkers are obtained by treatment of oxalyl chloride and amine of the Formula V.

39. (Cancelled)